➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Moodys
McKinsey
McKesson
Dow
Harvard Business School
Mallinckrodt

Last Updated: March 7, 2021

DrugPatentWatch Database Preview

ADVIL ALLERGY SINUS Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

When do Advil Allergy Sinus patents expire, and what generic alternatives are available?

Advil Allergy Sinus is a drug marketed by Glaxosmithkline and is included in one NDA. There is one patent protecting this drug.

This drug has thirty-four patent family members in eighteen countries.

The generic ingredient in ADVIL ALLERGY SINUS is chlorpheniramine maleate; ibuprofen; pseudoephedrine hydrochloride. There are twenty-nine drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the chlorpheniramine maleate; ibuprofen; pseudoephedrine hydrochloride profile page.

US ANDA Litigation and Generic Entry Outlook for Advil Allergy Sinus

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be February 28, 2027. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Start Trial

Summary for ADVIL ALLERGY SINUS
International Patents:34
US Patents:1
Applicants:1
NDAs:1
Suppliers / Packagers: 1
Formulation / Manufacturing:see details
What excipients (inactive ingredients) are in ADVIL ALLERGY SINUS?ADVIL ALLERGY SINUS excipients list
DailyMed Link:ADVIL ALLERGY SINUS at DailyMed
Drug patent expirations by year for ADVIL ALLERGY SINUS
Generic Entry Opportunity Date for ADVIL ALLERGY SINUS
Generic Entry Date for ADVIL ALLERGY SINUS*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for ADVIL ALLERGY SINUS

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Glaxosmithkline ADVIL ALLERGY SINUS chlorpheniramine maleate; ibuprofen; pseudoephedrine hydrochloride TABLET;ORAL 021441-001 Dec 19, 2002 OTC Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Colorcon
McKesson
Dow
Johnson and Johnson
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.